SwitzerlandSwitzerland

Clariant to take over German Süd-Chemie AG for EUR2bn

18.02.2011

Muttenz/Munich – Swiss chemistry specialist Clariant AG had made a 2bn bid for Munich-based catalysis and adsorbents specialist Süd-Chemie aimed at taking over the controlling majority from two groups of stockholders. The transaction, which is based on definite agreements with One Equity Partners who hold 50.4% of Süd-Chemie’s shares and the family shareholders (46%), is still subject to clearance by competent merger control authorities. When the deal goes through, Clariant will bag more than 95% of the outstanding shares. Süd-Chemie has a strong R&D pipeline that addresses future needs of the chemistry industry. The company has developed a economically promising approach in advanced development stage to generate cellulosic ethanol from the world’s most common straw feeds – rice straw, corn stover and bagasse. The Sun Liquid process, which has been proven economically feasible at pilot scale, is ready to be tested in a demonstration plant later this year. The company aimed at licensing out the technology world-wide as entry point to plant-based C-2 chemistry building blocks for manufacture of bulk bioplastics such as polyethylene, polypropylene or polyvinyl chloride. As a global leader in process catalysis and adsorbents Süd-Chemie provides the missing link between chemical process engineering and biocatalysis. In 2010, the Munich-based company had a turnover of EUR1.225 billion and EBITDA of EUR 191 million. After the acquisition of Danish Danico by US chemistry giant DuPont, Süd-Chemie has become is the second strategic target involving a world-leading biotechnology product pipeline. The issue of new shares is subject to approval at the Clariant general meeting on March 31, 2011.

SwitzerlandSwitzerland

11.11.2011

Ghent/Geneva - Ablynx rides the biotech rollercoaster. Only days after US-pharma company Pfizer pulled out of a rheumatoid arthritis pact, the Belgian bipharmaceutical outfit expanded its relationship with Merck Serono. Ablynx...

SwitzerlandSwitzerland

10.11.2011

Alschwil - Actelion Ltd. gets a badly needed injection of fresh capital. Under the guidance of the two biggest Swiss banks, UBS and Credit Suisse, the Swiss biopharmaceutical company takes up €171 million agreeing to pay a 4,875%...

SwitzerlandSwitzerland

18.10.2011

Basel/San Diego –Swiss drug company Roche has announced it is buying biotech-company Anadys Pharmaceuticals for US$230 million. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all...

Germany, SwitzerlandSwitzerland

12.10.2011

The Swiss technology transfer organisation Unitectra is the winner of the European Biotechnica Award 2011. The specialist for technology transfer received the award from hands of Lower Saxony's Minister for Economy Jörg Bode. The...

SwitzerlandSwitzerland

01.10.2011

Liestal – Swiss Santhera AG has announced strict savings measures. Out of a total of 21 employees, almost every second is now slated to be sacked. The biotech firm is closing its department of preclinical development and scaling...

SwitzerlandSwitzerland

01.10.2011

Schlieren – Swiss biotechnology company Cytos AG has finally devised a plan to help its lead candidate into Phase II, but to achieve it, the cash-strapped company is having to slash its workforce by a whopping 85%. To ensure the...

SwitzerlandSwitzerland

01.10.2011

Geneva – Swiss biotech Addex Pharmaceuticals AG has regained all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) programme from Merck&Co, (known as MSD outside the United States and...

SwitzerlandSwitzerland

01.10.2011

Hamburg – When the compound EVT302 failed proof-of-concept testing in the spring of 2009, investors began backing away from Evotec AG shares. Now the selective MAO-B inhibitor is back, and has powered a leap in the company’s...

SwitzerlandSwitzerland

15.09.2011

Zurich – The FDA has posted a manufacturing warning to Lonza following an inspection of the firm's microbial production site for Eisai’s cancer drug Ontak in Hopkinton. However, analysts at Vontobel said that the impact of the...

SwitzerlandSwitzerland

30.08.2011

Schlieren - Swiss biotechnology company Cytos has devised a plan to get its lead candidate into Phase II. To achieve this, the cash strapped company will slash its workforce, as previously announced, by 85%. To ensure the...

Displaying results 21 to 30 out of 276

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/2/article/clariant-to-take-over-german-sued-chemie-ag-for-eur2bn.html

Product of the week

Products

Events

All Events

Current issue

All issues